ES2673028T3 - Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas - Google Patents

Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas Download PDF

Info

Publication number
ES2673028T3
ES2673028T3 ES11847833T ES11847833T ES2673028T3 ES 2673028 T3 ES2673028 T3 ES 2673028T3 ES 11847833 T ES11847833 T ES 11847833T ES 11847833 T ES11847833 T ES 11847833T ES 2673028 T3 ES2673028 T3 ES 2673028T3
Authority
ES
Spain
Prior art keywords
genes
trinucleotide repeats
selective reduction
prolonged
harmful activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11847833T
Other languages
English (en)
Inventor
Tzu-Hao Cheng
Chia-Rung Liu
Tzu-Han Wang
Stanley N. Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Yang Ming University NYMU
Leland Stanford Junior University
Original Assignee
National Yang Ming University NYMU
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Yang Ming University NYMU, Leland Stanford Junior University filed Critical National Yang Ming University NYMU
Application granted granted Critical
Publication of ES2673028T3 publication Critical patent/ES2673028T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)

Abstract

Un agente para el uso en la modificación de la progresión en un sujeto de una enfermedad que surge de un gen que contiene un dominio de repeticiones de trinucleótidos prolongadas mutantes, en el que la administración al sujeto de una cantidad eficaz del agente reduce de manera selectiva una actividad transcripcional mediada por SPT4, para reducir de manera selectiva la actividad perjudicial del gen para modificar la progresión de la enfermedad en el sujeto.
ES11847833T 2010-12-10 2011-12-08 Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas Active ES2673028T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TW99143336 2010-12-10
US13/110,494 US8569254B2 (en) 2010-12-10 2011-05-18 Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same
US201161513970P 2011-08-01 2011-08-01
PCT/US2011/063997 WO2012078906A2 (en) 2010-12-10 2011-12-08 Selective reduction of the deleterious activity of extended tri-nucleotide repeat containing genes

Publications (1)

Publication Number Publication Date
ES2673028T3 true ES2673028T3 (es) 2018-06-19

Family

ID=45528877

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11847833T Active ES2673028T3 (es) 2010-12-10 2011-12-08 Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas

Country Status (7)

Country Link
US (6) US8569254B2 (es)
EP (2) EP2463372B1 (es)
JP (1) JP5769084B2 (es)
ES (1) ES2673028T3 (es)
TR (1) TR201808029T4 (es)
TW (1) TWI430812B (es)
WO (1) WO2012078906A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569254B2 (en) 2010-12-10 2013-10-29 National Yang Ming University Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same
CN107614686A (zh) 2015-05-29 2018-01-19 小利兰·斯坦福大学托管委员会 用于降低含有延伸的核苷酸重复序列的基因的有害活性的核苷试剂
AU2016335032B2 (en) * 2015-10-05 2022-04-14 Proqr Therapeutics Ii B.V. Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion
KR20180136905A (ko) * 2017-06-15 2018-12-26 주식회사 툴젠 반복 확장 돌연변이에 대한 게놈 편집 시스템
EP3641758A4 (en) * 2017-06-19 2021-03-17 The Board of Trustees of the Leland Stanford Junior University COMPOUNDS FOR REDUCING DELETE ACTIVITY OF GENES CONTAINING WIDE REPETITION OF NUCLEOTIDES
TWI796420B (zh) * 2018-01-22 2023-03-21 國立陽明交通大學 提升ｓｕｐｔ４ｈ在細胞中核苷酸重複序列擴張基因之轉錄調控能力的方法
US20210238226A1 (en) * 2018-05-22 2021-08-05 Design Therapeutics, Inc. Methods and compounds for the treatment of genetic disease

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US7255851B2 (en) 1994-07-01 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US6217847B1 (en) 1994-07-01 2001-04-17 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
NZ502323A (en) 1996-06-04 2001-09-28 Univ Utah Res Found Monitoring a fluorescence energy transfer pair during hybridization of first probe labelled with fluorescein to second probe labelled with Cy5 or Cy5.5
DK0877600T3 (da) 1996-08-09 2004-02-02 Alcon Mfg Ltd Konserveringssystem til farmaceutiske præparater indeholdende cyclodextrine
US6376257B1 (en) 1997-04-24 2002-04-23 University Of Rochester Detection by fret changes of ligand binding by GFP fusion proteins
US6642001B1 (en) 1999-07-13 2003-11-04 Whitehead Institute For Biomedical Research Generic SBE-FRET protocol
KR20030022762A (ko) 1999-10-26 2003-03-17 델타젠, 인코포레이티드 Ｔｒｐ 유전자 파괴를 포함하는 형질전환 마우스
AU2002221848A1 (en) 2000-11-16 2002-05-27 Belik, Daniel Dye pair for fluorescence resonance energy transfer (fret) measurements
US20050277133A1 (en) * 2001-05-18 2005-12-15 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US20050096284A1 (en) * 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20080176812A1 (en) 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
US20050020521A1 (en) * 2002-09-25 2005-01-27 University Of Massachusetts In vivo gene silencing by chemically modified and stable siRNA
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US20040152651A1 (en) 2002-11-01 2004-08-05 Rana Tariq M. Regulation of transcription elongation factors
CN1735808A (zh) 2002-11-07 2006-02-15 鹿特丹伊拉兹马斯大学 用于检测相互作用的分子的fret探针和方法
US8680063B2 (en) * 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
ES2808561T3 (es) 2003-09-12 2021-03-01 Univ Massachusetts Interferencia por ARN para el tratamiento de trastornos de ganancia de función
CA2602120A1 (en) 2005-03-25 2006-10-05 The Uab Research Foundation Methods of altering gene expression and methods of treatment utilizing same
JP4921458B2 (ja) 2005-04-04 2012-04-25 ブルーシフト・バイオテクノロジーズ・インコーポレーテッド Ｆｒｅｔ発光における偏光異方性を使用したスクリーニングの方法
JP2009504782A (ja) * 2005-08-18 2009-02-05 アルナイラム ファーマシューティカルズ インコーポレイテッド 神経疾患を治療するための方法および組成物
US7375190B2 (en) * 2006-09-19 2008-05-20 National Yang-Ming University Recombinant protein and method of screening for agents that modulate polypeptide aggregation
JP5866283B2 (ja) * 2009-07-28 2016-02-17 サンガモ バイオサイエンシーズ， インコーポレイテッド トリヌクレオチド反復疾患を治療するための方法および組成物
SI2475675T1 (sl) * 2009-09-11 2017-03-31 Ionis Pharmaceuticals, Inc. Modulacija ekspresije huntingtina
EP2536738A4 (en) * 2010-02-08 2014-09-17 Isis Pharmaceuticals Inc METHODS AND COMPOSITIONS SUITABLE FOR THE TREATMENT OF CONDITIONS OR CONDITIONS IN RELATION TO THE EXPANSION OF REPETITIONS
US8569254B2 (en) 2010-12-10 2013-10-29 National Yang Ming University Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same

Also Published As

Publication number Publication date
EP2463372A1 (en) 2012-06-13
US20180171336A1 (en) 2018-06-21
US20130331437A1 (en) 2013-12-12
US20120149754A1 (en) 2012-06-14
US20160116456A1 (en) 2016-04-28
EP2705151A2 (en) 2014-03-12
US20160152978A1 (en) 2016-06-02
WO2012078906A2 (en) 2012-06-14
TWI430812B (zh) 2014-03-21
WO2012078906A3 (en) 2012-10-04
US9226935B2 (en) 2016-01-05
US10760077B2 (en) 2020-09-01
US8569254B2 (en) 2013-10-29
TR201808029T4 (tr) 2018-06-21
EP2705151B1 (en) 2018-03-21
JP5769084B2 (ja) 2015-08-26
JP2012125240A (ja) 2012-07-05
EP2705151A4 (en) 2014-10-08
US9211303B2 (en) 2015-12-15
EP2463372B1 (en) 2015-09-02
US9862947B2 (en) 2018-01-09
US20130317088A1 (en) 2013-11-28
US9637741B2 (en) 2017-05-02
TW201223545A (en) 2012-06-16

Similar Documents

Publication Publication Date Title
ES2673028T3 (es) Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
BR112013021509A2 (pt) composições para cuidado pessoal
BR112013019702A2 (pt) composições dentais compreendendo agente de adição-fragmentação etilenicamente insaturado.
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
EA201591405A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
NI201600071A (es) Compuestos de inhibidor de autotaxina
DOP2012000245A (es) Composiciones sólidas
LT2811998T (lt) Paraziticidinės peroralinės veterinarinės kompozicijos, apimančios sistemiškai veikiančius aktyviuosius agentus, būdai ir jų panaudojimas
PE20171763A1 (es) Composiciones y metodos para inhibir la expresion del gen hao1 (hidroxiacido-oxidasa 1 (glicolato-oxidasa))
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
RS53124B (en) USE OF BETANECOL FOR THE TREATMENT OF XEROSOMOMY
UA112086C2 (uk) Гербіцидні композиції, що включають хлорацетаміди
CL2008000188A1 (es) Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
EA201591401A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
MX2013008500A (es) Disialillacto-n-tetraosa (dslnt) o variantes, isomeros, analogos y derivados de la misma para prevenir o inhibir la enfermedad del intestino.
JP2013541099A5 (es)
CO6700840A2 (es) Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia
CL2015001180A1 (es) Combinacion farmaceutica que comprende un copolimero de carboximetilcelulosa sodica con un grado de sustitucion de 0,35 a 0,80 y gosipol o un medicamento para el tratamiento de trastornos cognitivos seleccionado de neurolepticos, antidepresivos, anticonvulsivos o una combinacion de los mismos.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
BR112013019924A8 (pt) Composições para cuidado oral
IN2015DN02645A (es)